Alzheimer's disease (AD) is a progressive neurodegenerative disorder with devastating
effects. The greatest risk factor to develop AD is age. Today, only symptomatic therapies are …

Neurodegenerative diseases are a broad group of largely debilitating, and ultimately
terminal conditions resulting in progressive degeneration of different brain regions. The …

Abstract Alzheimer's disease (AD), as a common age‐related dementia, is a progressive
manifestation of cognitive decline following synaptic failure resulted majorly by senile …

Understanding the structural and assembly dynamics of the amyloid β-protein (Aβ) has
direct relevance to the development of therapeutic agents for Alzheimer disease. To …

Alzheimer's disease (AD) is a progressive neurodegenerative disorder, for which blocking
the early steps of extracellular misfolded amyloid-β (Aβ) aggregation is a promising …

Amyloid beta (Aβ) peptides derived from proteolytic cleavage of amyloid precursor protein
(APP) are thought to be a pivotal toxic species in the pathogenesis of Alzheimer's disease …

The discovery of drugs for Alzheimer's disease (AD) therapy that can also permeate the
blood brain barrier (BBB) is very difficult owing to its specificity and restrictive nature. The …

Self-assembly of amyloid β-protein (Aβ) into neurotoxic oligomers and fibrillar aggregates is
a key process thought to be the proximal event leading to development of Alzheimer's …

A proline-rich polypeptide complex (PRP), subsequently called Colostrinin™(CLN), was first
isolated from ovine colostrum, was shown to possess immunoregulatory properties …

Inhibition of amyloid β-protein (Aβ)-induced toxicity is a promising therapeutic strategy for
Alzheimer's disease (AD). Previously, we reported that the C-terminal tetrapeptide Aβ (39 …